DE10034494B4 - Verfahren zur Herstellung eines Extrakts von amerikanischem Ginseng - Google Patents
Verfahren zur Herstellung eines Extrakts von amerikanischem Ginseng Download PDFInfo
- Publication number
- DE10034494B4 DE10034494B4 DE10034494A DE10034494A DE10034494B4 DE 10034494 B4 DE10034494 B4 DE 10034494B4 DE 10034494 A DE10034494 A DE 10034494A DE 10034494 A DE10034494 A DE 10034494A DE 10034494 B4 DE10034494 B4 DE 10034494B4
- Authority
- DE
- Germany
- Prior art keywords
- extract
- american ginseng
- filtrate
- ethanol
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 46
- 239000000284 extract Substances 0.000 title claims abstract description 45
- 240000005373 Panax quinquefolius Species 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 21
- 230000008569 process Effects 0.000 title claims abstract description 8
- 239000000706 filtrate Substances 0.000 claims abstract description 22
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 14
- 239000006228 supernatant Substances 0.000 claims abstract description 9
- 239000012528 membrane Substances 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 239000012465 retentate Substances 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- 235000008434 ginseng Nutrition 0.000 claims description 20
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- 208000011906 peptic ulcer disease Diseases 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 6
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 201000005917 gastric ulcer Diseases 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 230000002441 reversible effect Effects 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 208000000718 duodenal ulcer Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 240000004371 Panax ginseng Species 0.000 description 20
- 241000700159 Rattus Species 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 12
- 208000032843 Hemorrhage Diseases 0.000 description 10
- 235000002789 Panax ginseng Nutrition 0.000 description 9
- 231100000397 ulcer Toxicity 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 235000015961 tonic Nutrition 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 235000002791 Panax Nutrition 0.000 description 2
- 241000208343 Panax Species 0.000 description 2
- 241000168720 Panax japonicus Species 0.000 description 2
- 235000003174 Panax japonicus Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000013289 male long evans rat Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241001649012 Cypselea humifusa Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 206010042209 Stress Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000008430 aponin Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE20023736U DE20023736U1 (de) | 2000-01-11 | 2000-07-11 | Pharmazeutische Zusammensetzung gegen Ulkus |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW089100334A TWI222357B (en) | 2000-01-11 | 2000-01-11 | Anti-ulcer pharmaceutical composition and the preparation and use thereof |
| TW89100334 | 2000-01-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE10034494A1 DE10034494A1 (de) | 2001-07-19 |
| DE10034494B4 true DE10034494B4 (de) | 2006-04-27 |
Family
ID=21658438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10034494A Expired - Lifetime DE10034494B4 (de) | 2000-01-11 | 2000-07-11 | Verfahren zur Herstellung eines Extrakts von amerikanischem Ginseng |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US6962719B1 (fr) |
| JP (1) | JP3453114B2 (fr) |
| DE (1) | DE10034494B4 (fr) |
| FR (1) | FR2797401B1 (fr) |
| TW (1) | TWI222357B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5033292B2 (ja) * | 2002-09-03 | 2012-09-26 | 株式会社武蔵野免疫研究所 | 損傷した組織の修復を促進する組成物 |
| WO2012148277A1 (fr) * | 2011-04-29 | 2012-11-01 | Unilever N.V. | Procédé d'isolement de polysaccharides |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3609005A1 (de) * | 1984-11-22 | 1987-09-24 | Seuref Ag | Pharmazeutische zusammensetzungen mit metabolischer aktivitaet |
| DE3328262C2 (fr) * | 1982-08-25 | 1988-05-05 | Tsumura Juntendo Inc., Tokio/Tokyo, Jp | |
| US5459041A (en) * | 1988-02-18 | 1995-10-17 | Enteric Research Laboratories, Inc. | Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5391109A (en) | 1977-01-20 | 1978-08-10 | Koshiro Chiyuuji Shiyouten Kk | Antitumor agent |
| JPS54135210A (en) | 1978-04-07 | 1979-10-20 | Shigeru Yuuchi | Tumor treating agent |
| JPS5626818A (en) * | 1979-08-13 | 1981-03-16 | Osaka Chem Lab | Glucocorticoid drug |
| US4795742A (en) * | 1985-09-24 | 1989-01-03 | Yaguang Liu | Therapeutic composition from plant extracts |
| JP3121850B2 (ja) | 1991-02-28 | 2001-01-09 | 日東電工株式会社 | 酸分泌抑制物質の単離方法 |
| US6432454B1 (en) | 1997-12-12 | 2002-08-13 | C. V. Technologies, Inc. | Processes of making north american ginseng fractions, products containing them, and use as immunomodulators |
| GB2364640B (en) | 2000-07-11 | 2002-12-04 | Pharmaceutical Ind Tech & Dev | Anti-ulcer pharmaceutical composition and the preparation thereof |
-
2000
- 2000-01-11 TW TW089100334A patent/TWI222357B/zh not_active IP Right Cessation
- 2000-03-09 US US09/522,434 patent/US6962719B1/en not_active Expired - Lifetime
- 2000-07-11 DE DE10034494A patent/DE10034494B4/de not_active Expired - Lifetime
- 2000-07-31 FR FR0010072A patent/FR2797401B1/fr not_active Expired - Lifetime
- 2000-08-18 JP JP2000248299A patent/JP3453114B2/ja not_active Expired - Lifetime
-
2002
- 2002-05-06 US US10/139,482 patent/US6800304B2/en not_active Expired - Lifetime
-
2004
- 2004-05-20 US US10/850,217 patent/US6991815B2/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3328262C2 (fr) * | 1982-08-25 | 1988-05-05 | Tsumura Juntendo Inc., Tokio/Tokyo, Jp | |
| DE3609005A1 (de) * | 1984-11-22 | 1987-09-24 | Seuref Ag | Pharmazeutische zusammensetzungen mit metabolischer aktivitaet |
| US5459041A (en) * | 1988-02-18 | 1995-10-17 | Enteric Research Laboratories, Inc. | Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection |
Non-Patent Citations (10)
| Title |
|---|
| Datenbank CAPLUS bei STN, AN 1997:778804 zu: Effect of ginseng extracts on production of vacuolating toxin by Helicobacter pylori. Chang, M.-W. u.a., Taehan Misaengmul Hakhoechi (1997), 32(5), 539-551 [rech. am 21.03.01] * |
| JP 02-234696 A (abstracts), In: Pat. Abstr. of Jp. [CD-ROM] |
| JP 02234696 A (abstracts), In: Pat. Abstr. of Jp.[CD-ROM] * |
| JP 04-273824 A (abstracts), In: Pat. Abstr. of Jp. [CD-ROM] |
| JP 04273824 A (abstracts), In: Pat. Abstr. of Jp.[CD-ROM] * |
| JP 3121850 B2 (abstract), WPI/Derwent abstract AN:1992-375618 * |
| JP 54-135210 A (abstract), WPI/Derwent abstract AN:1979-86683B |
| JP 54135210 A (abstract), WPI/Derwent abstract AN:1979-86683B * |
| JP 56-043214 A (abstracts), In: Pat. Abstr. of Jp. [CD-ROM] |
| JP 56043214 A (abstracts), In: Pat. Abstr. of Jp.[CD-ROM] * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2797401B1 (fr) | 2005-02-11 |
| JP3453114B2 (ja) | 2003-10-06 |
| US6962719B1 (en) | 2005-11-08 |
| TWI222357B (en) | 2004-10-21 |
| US6991815B2 (en) | 2006-01-31 |
| FR2797401A1 (fr) | 2001-02-16 |
| US20020187209A1 (en) | 2002-12-12 |
| US6800304B2 (en) | 2004-10-05 |
| JP2001192340A (ja) | 2001-07-17 |
| US20040213860A1 (en) | 2004-10-28 |
| DE10034494A1 (de) | 2001-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0089529B1 (fr) | Concentrés de polysaccharides, procédé pour leur préparation et médicaments et compositions cosmétiques les contenant | |
| DE3040246A1 (de) | Saponine, verfahren zu deren gewinnung und diese verbindungen enthaltende arzneimittel | |
| CH659948A5 (de) | Mittel zur verstaerkung der antitumor-wirksamkeit von mitomycin-c und doxorubicin-hydrochlorid. | |
| DE112005001269T5 (de) | Polysaccharidextrakt aus Lycium barbarum als neuroprotektives Mittel gegen ß-Amyloidpeptidneurotoxizität | |
| DE19756848C2 (de) | Extrakte aus Blättern von Ginkgo biloba mit vermindertem Gehalt an 4'-O-Methylpyridoxin und Biflavonen | |
| AT391315B (de) | Verfahren zur herstellung von isosilybinfreiem silibinin | |
| DE10235465A1 (de) | Neue chinesische Kräuterzusammensetzung zur Verbesserung der Blutzirkulation sowie Verfahren zum Herstellen derselben | |
| EP0904092B1 (fr) | Extrait purifie d'harpagophytum procumbens et/ou d'harpagophytum zeyheri dence, procede permettant de le preparer et utilisation | |
| EP0281656B1 (fr) | Utilisation d'extraits de pétasites pour la préparation d'un médicament pour le traitement de maladies gastro-intestinales | |
| DE2137011C3 (de) | Verfahren zur Gewinnung reinen Konjakumannans und daraus hergestelltes pharmazeutisches Präparat | |
| DE10034494B4 (de) | Verfahren zur Herstellung eines Extrakts von amerikanischem Ginseng | |
| DE102017204379A1 (de) | Herstellungsverfahren eines wasserlöslichen Ginkoblattextrakts und wasserlöslicher Ginkoblattextrakt | |
| EP1089748B2 (fr) | Extrait sec hydrosoluble de ginkgo biloba presentant une teneur elevee en terpenoides et flavonglycosides | |
| DE60213211T2 (de) | Verfahren zur gewinnung von dekokten aus schalen von vitis labrusca und vitis vinifera | |
| DE19823679A1 (de) | Verwendung von Crataegus-Zubereitungen zur Prophylaxe und Therapie neoplastischer Erkrankungen | |
| DE2342460A1 (de) | Eisen- oder aluminiumglycyrrhizinat enthaltendes produkt, verfahren zu seiner herstellung und dieses produkt enthaltendes arzneimittel | |
| DE20023736U1 (de) | Pharmazeutische Zusammensetzung gegen Ulkus | |
| GB2364640A (en) | Composition for the treatment of peptic ulcer comprising American ginseng | |
| DE10319109B4 (de) | Verfahren zur Herstellung eines Extraktes von Cynanchum Atratum oder Cynanchum Versicolor und dessen Verwendung als Antitussivum | |
| EP1530971B1 (fr) | Composition pour le traitment des maladies de la dent et de la gencive | |
| WO2003084554A1 (fr) | Extrait de saule | |
| DE60133669T2 (de) | Zusammensetzungen zur auslösung der sekretion des insulinähnlichen wachstumsfaktors 1 | |
| DE102021006355A1 (de) | Pharmazeutische Zusammensetzung zur Behandlung von seborrhoischer Dermatitis | |
| EP1750735A1 (fr) | Utilisation d'un extrait d'aloysia/verbena/lippia triphylla/citriodora pour traiter des affections chroniques et/ou inflammatoires | |
| DE19740509A1 (de) | Verwendung eines Weißdornfrüchte- und/oder -blätter/blütenextraktes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8127 | New person/name/address of the applicant |
Owner name: MEDICAL AND PHARMACEUTICAL INDUSTRY TECHNOLOGY AND |
|
| 8364 | No opposition during term of opposition | ||
| R071 | Expiry of right |